Health, Health Insurance, and Disability Statistics from the Census Bureau

This presentation features: What is health?; Census Bureau mission; What questions on health can we answer with Census Bureau statistics?; Census Bureau Statistics on Health; Health care needs: Population Counts; Aging; Health Status; Health Status and Medical Utilization; Fertility; ACS Disability Questions; Disability Prevalence by State; Percentage of People with a Disability; Disability Prevalence by Age: 2010; Unemployment Rate; Employment to Population Ratios for People 18 to 64 years with a Disability by State; Veterans: Service Connected Disability; Health Insurance by type and across time; Health Insurance by type, small geography, many variables; Small Geography by Insured/Not insured; Medical Out Of Pocket Expenses; Work Interruption for Family Care; Industry and Occupation; Health care occupations; Subnational Economic Data Sources About Businesses and Governments; County Business Patterns; EEO Tabulation; Disability Employment Tabulation; Which source best fits your needs?; Content and Geography; Census 2010: Demographics Across Geographies; Population Estimates; Current Population Survey Annual Social and Economic Supplement; American Community Survey: Content; Geography of ACS; Survey of Income and Program Participation; Coming December 5, 2013: Health Insurance and Disability Statistics for all Geographies from the ACS 5-year file; Health Insurance Base Tables in ACS 5‐year file; Disability Base Tables in ACS 5‐year file; How to access these data?; Easy Access to Census Statistics; SAHIE Interactive Data Tool; SAHIE Interactive Tool Data Tab, Map and Trends; Census API; APIs provide new methods of data dissemination; APIs: Spurring innovation around Census statistics and Online resources; Easy Stats: Thematic access to ACS data; New QuickFacts Data Tool; How do I find all this?; New Topic Based Web Pages; Nesting under broad topics; Health Page; Research and Future Enhancements; Health Insurance Question Changes in the CPS ASEC; Small Area Estimates Development Project; and Upcoming Release Schedule

Equal Employment Opportunity Tabulation 2006-2010

This presentation features: What do you do?; 1790 Census; Composition of the Labor Force by Sex; By Race and Hispanic Origin; Occupation; Occupation and Industry; Shifting shares for each occupation for men and women; States and Metros; More detailed geography; Why do we need the Equal Employment Opportunity tabulation?; U.S. Equal Employment Opportunity Commission; Overview of the Equal Employment Opportunity Tabulation; What can this tabulation tell you?; Largest Dataset on American FactFinder; 5 Decades of Equal Employment Opportunity Tabulations; Primary Purpose of the Equal Employment Opportunity Tabulation; Sponsoring Agencies; Civil Rights Laws; What’s in it?; New this time; New Measures; Source Data: American Community Survey (ACS); American Community Survey Similarities with Census 2000 Long-Form Sample; Five-Year Estimates; Race and Ethnicity Categories; Levels of Geography; Kinds of Location; Commuting Flows; Table Sets and Iterations; Disclosure Avoidance; Thresholds by Table Set; Table ID Codes on AFF; Box Head and Table Display; Margins of Error; 3 Ways to Access the EEO Tabulation; Equal Employment Opportunity Subject Web page; American FactFinder; Not your standard geography: County Sets; FTP Download; The Disability Employment Tabulation 2008-2010; Sponsoring Agencies; Importance; Comparison with EEO Tab; Table Set Geography and Variables; Race and Ethnicity Categories; and Disability Employment Tabulation Subject Webpage on census.gov

An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial

Background There is no vaccine against the major global pathogen Chlamydia trachomatis; its different serovars cause trachoma in the eye or chlamydia in the genital tract. We did a clinical trial administering CTH522, a recombinant version of the C trachomatis major outer membrane molecule, in different dose concentrations with and without adjuvant, to establish its safety and immunogenicity when administered intramuscularly, intradermally, and topically into the eye, in prime-boost regimens. Methods CHLM-02 was a phase 1, double-blind, randomised, placebo-controlled trial at the National Institute for Health Research Imperial Clinical Research Facility, London, UK. Participants were healthy men and non-pregnant women aged 18–45 years, without pre-existing C trachomatis genital infection. Participants were assigned into six groups by the electronic database in a pre-prepared randomisation list (A–F). Participants were randomly assigned (1:1:1:1:1) to each of the groups A–E (12 participants each) and 6 were randomly assigned to group F. Investigators were masked to treatment allocation. Groups A–E received investigational medicinal product and group F received placebo only. Two liposomal adjuvants were compared, CAF01 and CAF09b. The groups were intramuscular 85 μg CTH522-CAF01, or placebo on day 0 and two boosters or placebo at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (A); intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional topical ocular administration of CTH522, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (B); intramuscular 85 μg CTH522-CAF01, two boosters at day 28 and 112 with additional intradermal administration of CTH522, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (C); intramuscular 15 μg CTH522-CAF01, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (D); intramuscular 85 μg CTH522-CAF09b, two boosters at day 28 and 112, and a mucosal recall with either placebo or CTH522 topical ocularly at day 140 (E); intramuscular placebo (F). The primary outcome was safety; the secondary outcome (humoral immunogenicity) was the percentage of trial participants achieving anti-CTH522 IgG seroconversion, defined as four-fold and ten-fold increase over baseline concentrations. Analyses were done as intention to treat and as per protocol. The trial is registered with ClinicalTrials.gov, NCT03926728, and is complete. Findings Between Feb 17, 2020 and Feb 22, 2022, of 154 participants screened, 65 were randomly assigned, and 60 completed the trial (34 [52%] of 65 women, 46 [71%] of 65 White, mean age 26·8 years). No serious adverse events occurred but one participant in group A2 discontinued dosing after having self-limiting adverse events after both placebo and investigational medicinal product doses. Study procedures were otherwise well tolerated; the majority of adverse events were mild to moderate, with only seven (1%) of 865 reported as grade 3 (severe). There was 100% four-fold seroconversion rate by day 42 in the active groups (A–E) and no seroconversion in the placebo group. Serum IgG anti-CTH522 titres were higher after 85 μg CTH522-CAF01 than 15 μg, although not significantly (intention-to-treat median IgG titre ratio groups A–C:D=5·6; p=0·062), with no difference after three injections of 85 μg CTH522-CAF01 compared with CTH522-CAF09b (group E). Intradermal CTH522 (group C) induced high titres of serum IgG anti-CTH522 neutralising antibodies against serovars B (trachoma) and D (urogenital). Topical ocular CTH522 (group B) at day 28 and 112 induced higher total ocular IgA compared with baseline (p<0·001). Participants in all active vaccine groups, particularly groups B and E, developed cell mediated immune responses against CTH522. Interpretation CTH522, adjuvanted with CAF01 or CAF09b, is safe and immunogenic, with 85 μg CTH522-CAF01 inducing robust serum IgG binding titres. Intradermal vaccination conferred systemic IgG neutralisation breadth, and topical ocular administration increased ocular IgA formation. These findings indicate CTH522 vaccine regimens against ocular trachoma and urogenital chlamydia for testing in phase 2, clinical trials. Funding The EU Horizon Program TRACVAC

Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth

Background: We report findings from an experimental medicine study of rationally designed prefusion stabilised native-like HIV envelope glycoprotein (Env) immunogens, representative of global circulating strains, delivered by sequential intramuscular injection. Methods: Healthy adult volunteers were enrolled into one of five groups (A to E) each receiving a different schedule of one of two consensus Env immunogens (ConM SOSIP, ConS UFO, either unmodified or stabilised by chemical cross-linking, followed by a boost with two mosaic Env immunogens (Mos3·1 and Mos3·2). All immunogens were co-formulated with liposomal Monophosphoryl-Lipid A (MPLA) adjuvant, and volunteers were followed up for 28 days post final Mosaic booster injection. Participants gave written informed consent to join the study. The study is registered on ClinicalTrials.gov ID NCT03816137. Findings: Fifty-one participants (men n=23 and women n=28) aged 18-55 were enrolled. The seroconversion rate against Env was 100% with all participants having measurable anti-EnvIgG antibodies after their second injection and throughout the study. Neutralisation was detected against the ConM pseudovirus in sera of those who had received both ConM and ConS immunogens. However, this activity was limited in breadth and was neither boosted nor broadened in those receiving the Mos3·1 and Mos3·2 immunogens. Neutralising antibody function correlated with binding to V1/V3 and V5 epitopes and peaked after the third injection. Interpretation: Rationally designed prefusion-stabilised native-like Env trimers are robustly immunogenic in a prime-boost schedule. When given alone they are insufficient to induce neutralising antibody titres of significant breadth, but they represent potentially valuable polishing immunogens after germline-targeting. Funding: European Aids Vaccine initiative (EAVI2020) received funding from EU Horizon 2020, grant number 681137. Structural studies were supported by the Bill and Melinda Gates Foundation (INV-002916)